Inflammatory Bowel Disease Drivers Revealed in Human Organ Chips
================================================================

* Alican Özkan
* Gwenn Merry
* David B. Chou
* Ryan R. Posey
* Anna Stejskalova
* Karina Calderon
* Megan Sperry
* Viktor Horvath
* Lorenzo E. Ferri
* Emanuela Carlotti
* Stuart A. C. McDonald
* Douglas J. Winton
* Rocco Riccardi
* Lilianna Bordeianou
* Sean Hall
* Girija Goyal
* Donald E. Ingber

## **Abstract**

Inflammatory bowel disease (IBD) patients exhibit compromised intestinal barrier function and decreased mucus accumulation, as well as increased inflammation, fibrosis, and cancer risk, with symptoms often being exacerbated in women during pregnancy. Here, we show that these IBD hallmarks can be replicated using human Organ Chips lined by IBD patient-derived colon epithelial cells interfaced with matched fibroblasts cultured under flow. Use of heterotypic tissue recombinants revealed that IBD fibroblasts are the primary drivers of multiple IBD symptoms. Inflammation and fibrosis are accentuated by peristalsis-like motions in IBD Chips and when exposed to pregnancy-associated hormones in female IBD Chips. Carcinogen exposure also increases inflammation, gene mutations, and chromosome duplication in IBD Chips, but not in Healthy Chips. These data enabled by human Organ Chip technology suggest that the intestinal stroma and peristalsis-associated mechanical deformations play a key role in driving inflammation and disease progression in male and female IBD patients.

Keywords
*   Organ-on-a-chip
*   Ulcerative Colitis
*   Crohn’s Disease
*   Inflammation
*   Cancer
*   Carcinogenesis
*   Epithelial-Stromal Interactions
*   Women’s health

## Main

Inflammation of the intestinal mucosa, including enhanced production of inflammatory cytokines and tissue infiltration with immune cells, along with increased barrier permeability, thinning of the protective mucus layer, and fibrosis are central hallmarks of inflammatory bowel diseases (IBD), such as Crohn’s disease (Crohn’s) and ulcerative colitis (UC). These alterations lead to significant digestive issues and an increased risk of developing colorectal cancer1. IBD symptoms also can be more prominent in women2 and they have to control their symptoms before pregnancy because exacerbations increase the risk of preterm birth3. Most IBD treatments target immune cells rather than intestinal tissues, and treatment efficacy is variable among patients4. However, interactions between epithelia and underlying stroma also may contribute to inflammation as well as cancer progression5. For example, the presence of a subset of fibroblasts that recruit immune cells to the intestinal stem cell niche is associated with poor prognosis in patients with colorectal cancer6. Inflamed epithelial cells also can undergo an epithelial-to-mesenchymal transition and increase deposition of extracellular matrix (ECM) resulting in intestinal fibrosis that leads to complications, such as bowel stiffening and restriction of lumenal fluid flow, which further exacerbate digestive problems in IBD patients 7,8. Thus, there is a need to gain greater insight into how epithelial-stromal interactions, peristalsis, and fluid flow influence IBD development in both male and female patients. However, animal IBD models and in vitro studies with human intestinal cell lines lack direct relevance to the human disease9, and human intestinal organoids cannot be used to address these questions because they lack an epithelial-stromal interface, mucosal barrier, fluid flow, peristalsis motions, and immune cells, which are critical organ-level features required to address these questions.

Here, we leveraged human organ-on-a-chip (Organ Chip) microfluidic culture technology that recreates tissue-tissue interfaces and a physiologically relevant intestinal microenvironment including dynamic fluid flow, peristalsis-like mechanical deformations, and circulating immune cells to confront this challenge10,11. Colon Chips lined by human organoid-derived colonic epithelium cultured under dynamic fluid flow have been successfully used in the past to study mucus layer accumulation and physiology12,13 as well as to identify microbiome metabolites that influence host response to bacterial infections14. In this study, we isolated epithelium and stromal-derived fibroblasts from the same regions of colon from healthy or IBD patients and used them to create Colon Chips that contained an epithelial-fibroblast interface. We also created heterotypic tissue recombinant chips, measured the effects of applying peristalsis-like motions and flowing immune cells through the stromal channel, and studied the effects of female hormones on the IBD state, in addition to modeling cancer progression exposing the Colon Chips to carcinogens in vitro.

## Results

### Establishment of Human Healthy and IBD Colon Chips

Patient-specific epithelial organoids and stromal fibroblasts were isolated from surgical biopsies of the sigmoid colon of healthy and IBD patients with Crohn’s or UC (**Extended Data Fig. 1A** and **Supplementary Information**) and the organoids were expanded in Matrigel cultures while the fibroblasts were cultured on plastic dishes (**Extended Data Fig. 1B**). To build the human Colon Chips, the primary colon epithelial cells and fibroblasts were respectively seeded on the top and bottom surfaces of a porous ECM-coated membrane that separates two parallel channels within a commercially available microfluidic Organ Chip (**Fig. 1A**). The cells were allowed to adhere under static conditions for 1 day before flow was initiated. A continuous epithelial monolayer with undulating crypt-like structures formed by 11 days in Healthy Chips when viewed from above (**Fig. 1B,C****)** or in cross sections (**Fig. 1D,E**). The epithelium became progressively obscured by dense opaque deposits from day 3 to 7, which completely filled the upper channel by day 11 (**Fig. 1C**). These opaque materials have been shown to be composed of mucus with similar composition, thickness, and bilayer structure as seen in human colonic mucus in vivo 12,13. Similar chips lined with colonic epithelium and fibroblasts from Crohn’s or UC patient samples also formed hill and crypt-like structures, but significantly but significantly less mucus accumulated on top of the epithelium, particularly in the UC chips (**Fig. 1C** and **Extended Data Fig. 1C**) and the heights of the intestinal epithelium were significantly reduced as well (**Fig. 1E**). Epithelial cells within both Healthy and IBD Chips also expressed colon- specific cytokeratin 20 along their apical borders, while the basal stem cell marker SOX9 primarily appeared in their nuclei at the cell base (**Fig. 1F**), which is a hallmark of colon crypts in vivo 23.

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F1)

Figure 1: Primary human Colon Chips generated with epithelium and fibroblasts isolated from Healthy and IBD patient samples.
**A)** Photograph of the commercially available Organ Chip device (left) and a cross-sectional illustration of the epithelial-stromal tissue interface (right) formed with patient-derived cells, which is composed of a fibroblast rich stroma that is perfused with medium to mimic interstitial fluid flow separated by a flexible, porous, ECM- coated membrane from a colon epithelium above. The epithelium, which is composed of absorptive cells and Goblet cells, secretes a thick mucus layer into the lumen of the apical channel that also experiences fluid flow. The entire tissue-tissue interface can be stretched and relaxed rhythmically to mimic peristalsis-like motions by applying cyclic suction to hollow side chambers in the flexible device (not shown). **B)** Height of crypts formed in Colon Chips measured at 11 days. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n=3 Healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **C)** Representative bright field microscopic images of Healthy and IBD Chips created with cells from Crohn’s or UC patients viewed from above on day 3, 7, and 11. A functional epithelial monolayer progressively accumulated mucus, which appears as opaque blackened fuzzy material, in the apical channel of all chips over the 11 day time course; however, mucus accumulation was suppressed in the IBD Chips with the UC Chips displaying a greater reduction (bar, 500 µm)**. D)** Brightfield image of vertical cross-sections through healthy and IBD Colon chips showing that the crypt-like epithelial structures are shorter in the Crohn’s and UC Colon Chips (bar, 100 µm)**. E)** Histological H&E stained vertical cross-sections through healthy and IBD Colon chips confirming the presence of columnar colon epithelium containing goblet cells in healthy epithelium, and a significant reduction in the height of the epithelial monolayer with reduced numbers of goblet cells in the IBD Chips (bar, 50 µm). **F)** Immunofluorescence microscopic views showing distribution of SOX9 and CK20 in crypts in the colon epithelium of Healthy and IBD Chips (bar, 50 µm). **G**) Inflammatory cytokine protein levels measured in the basal outflows of Healthy (H) and IBD Chips on culture day 11 (n = 3-5 chips/ condition; chips were created with cells from 3 healthy (green), 2 Crohn’s (magenta), and 2 UC (cyan) patient donors, with each symbol represents a chip created with cells from a different patient. Numbers indicate *P* values between compared groups, as determined by two-tailed student’s t-test. All data represent mean + SD; *p* values are shown in all figures.

Past work has shown that there is a subset of stromal fibroblasts in IBD patients that have higher levels of expression of oncostatin M receptor (OSMR) and podoplanin (PDPN)6, which appear to play a significant role in inflammation, fibrosis, and cancer24. Indeed, when we carried out flow cytometric analysis after removing stromal cells from the chips, we found that PDPN expression was significantly higher in IBD fibroblasts that expressed high OSMR levels (**Extended Data Fig. 2A,B**) and that fibroblasts in IBD Chips lined by cells from both Crohn’s and UC patients secreted more inflammatory cytokines (e.g, IL6, IL8, MCP-1) from the basal channel than those in Healthy Chips (**Fig. 1G**). We also found that fibroblasts in IBD Chips established using both Crohn’s and UC patients samples express higher vimentin and α-SMA than healthy controls (**Extended Data Fig. 2C,D**), as previously observed in IBD mice models induced by treatment with DSS or IL10 knock out25.

Transcriptomic analysis of epithelial cells and fibroblasts individually within Healthy versus IBD Chips revealed that genes which were found to be overexpressed in Crohn’s and UC (e.g., ADA2, APOBEC3B, GSPT2, CD40, ACAN, HLA-DQB1) epithelium on-chip were also expressed at higher levels compared to healthy epithelium (**Extended Data Fig. 3A,B**). In addition, genes suppressed in IBD patient tissues in vivo (e.g., MUC5B, FDFT1 in Crohn’s and SOD3, SMIM32, APOBR in UC 26–30) were expressed at lower levels by epithelium in both Crohn’s and UC IBD Chips.

When stromal cells cultured in IBD Chips were similarly analyzed, they displayed expression of IBD-relevant genes with Crohn’s fibroblasts overexpressing ITGA7, FXD1, HGF, FZD7, NKX2-3, LOXL3 relative to healthy fibroblasts, while high levels of IKBIP, NKX2-3, ADA2, ECM2, NDN, SLC22A17 were seen in UC fibroblasts **(Extended Data.** **Fig. 3C,D**). In contrast, other genes were downregulated in these fibroblasts including NLRP2, FUCA1, CLCA4, and RNF186 in Crohn’s and RALGPS1, DLG3, STON2, and FMO5 in UC derived IBD Chips (**Extended Data Fig. 3C,D**), which is again consistent with results of transcriptomic analyses carried out on IBD patient tissues31–33.

Gene ontology and Reactome analysis revealed that multiple IBD-relevant biological processes, including increased ECM production and remodeling, cell adhesion, and angiogenesis as well as decreased metabolism were predominant in both Crohn’s and UC epithelium and fibroblasts on-chip, with UC tissues also exhibiting suppressed IL10 signaling (**Extended Data Fig. 4A-D**). These functional pathways are also activated or suppressed in a similar manner in IBD patients34.

### Peristalsis-Like Mechanical Motions Enhance IBD Progression

IBD patients experience thinning of the protective mucus layer in their colon12 and eventually loss of peristalsis as a consequence of increased fibrosis7,8, which further exacerbate their gastrointestinal symptoms. However, it is not known whether cyclic mechanical deformation of inflamed intestine or fluid flow due to peristalsis could influence IBD disease progression. To explore this possibility, we cultured Healthy and IBD Chips in the presence or absence of physiologically relevant cyclic deformations by applying suction to side chambers in the flexible devices. The healthy and IBD epithelia both accumulated a mucus layer when exposed to cyclic mechanical deformations were viewed by dark field imaging; however, the layer was much thinner in the IBD Chips (**Fig. 2A,B**). Transcriptomic analysis confirmed that the IBD Chips expressed lower levels of most mucins than Healthy Chips under all conditions, and that while expression of MUC-1,4,12,13,17,3A,5AC, and 5B increased in Healthy Chips exposed to mechanical strain, only MUC5AC and MUC13 increased in the IBD Chips (**Fig. 2C****)**. These data show that peristalsis-like mechanical deformations have a direct effect on mucus production in the colonic epithelium in both healthy and IBD Chips as fluid flow was constant under all conditions, and that the IBD epithelium is less effective at maintaining the normal thickness of the mucus layer in vitro as observed in IBD patients in vivo12,13.

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F2)

Figure 2: Peristalsis-like cyclic strain influences mucus production and fibrosis in Colon Chips.
**A)** Representative side-view images microscopy of Healthy or IBD Chips with (+) and without (-) exposure to mechanical deformations visualizing mucus layer accumulation (white diffuse material) in Healthy Chips using dark-field microscopy. Note that limited mucus was produced by IBD epithelium (bar, 1 mm). **B)** Quantification of the height of the mucus layer overlying Healthy and IBD epithelium on-chip when cultured under the conditions in A. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test. (n = 4 healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **C)** Heat map of genes showing that peristalsis-like mechanical stimulation (+) increases expression of genes related to mucus production in Healthy Chips, but not IBD Chips (n = 3 healthy, 1 Crohn’s and 2 UC). **D)** Second harmonic microscopic images of the fibroblast stroma in Healthy versus IBD Chips showing greater collagen fibril accumulation (green) with mechanical strain (+ Strain) in both chips, and that this response is greatly accentuated in IBD Chips (bar, 200 μm). **E)** Collagen fibril signal intensity in the stroma of Healthy versus IBD Chips quantified in second harmonic microscopic images. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n = 3 healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **F)** Heat map of genes showing that peristalsis-like cyclic strain enhances expression of genes associated with fibrillar collagen production in IBD fibroblasts, but not in healthy fibroblasts (n = 3 healthy, 1 Crohn’s and 2 UC). **G)** Heat maps of showing that cyclic strain enhances greater expression of IBD-associated inflammatory genes in IBD Chips compared to Healthy Chips both in epithelium and fibroblasts (n=3 Healthy, 1 Crohn’s, and 2 UC).

![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F3.medium.gif)

[Figure 3:](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F3)

Figure 3: Effects of ovarian hormones in Female Colon Chips.
**A)** Production of pro- inflammatory cytokine and chemokine proteins in Apical and Basal channels of Healthy versus IBD Chips 7 days post treatment with different female hormone exposures (E2, P4, and PAHs, as indicated). Note that exposure to female hormones significantly increased expression of inflammatory factors in both epithelium and fibroblast of IBD Colon Chips whereas they suppressed their production in Healthy Chips. **B)** Collagen fibril signal intensity in the stroma of Healthy versus IBD Chips quantified in second harmonic microscopic images showing that only exposure to pregnancy-like hormonal conditions produced a major increase in stromal fibrillogenesis, and this only was observed in IBD fibroblasts and not healthy fibroblasts from IBD patients. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n=4-6 chips of 1 Crohn’s and 1 Healthy patients from 2 independent experiments). **C)** Second harmonic microscopic images of fibrillar collagen (green) produced by fibroblasts showing that the E2 + E4 produce a small increase in fibrillogenesis in IBD Chips, while simulating pregnancy by exposure to E2 + E4 + PAH results in dramatic collagen fibril accumulation, and that neither of these responess are observed in Healthy Chips (bar, 200 μm; n=4-6 chips of 1 Crohn’s and 1 Healthy patients from 2 independent experiments).

Interestingly, second harmonic imaging of ECM fiber formation on-chip revealed that while both Crohn’s and UC derived IBD fibroblasts accumulate comparable fibrillar collagen as healthy cells, these levels increase many fold when the IBD Chips are exposed to peristalsis- like motions whereas there is no change in Healthy Chips (**Fig. 2D,E**). Atomic force microscopic analysis carried out in parallel samples from the biopsies we used to isolate the patient-derived cells confirmed that this was associated with tissue stiffening (**Extended Data Fig. 5A-D**). But while transcriptomic analysis showed that there is increased expression of collagen-associated genes in Crohn’s and UC stroma on-chip without mechanical strain, exposure to peristalsis-like deformations did not result in significant changes in collagen gene expression (**Fig. 2F**), suggesting that the fibrotic changes we observed resulted from post- transcriptional alterations. Indeed, pathway analysis confirmed that biological processes associated with fibrosis per se (ECM organization, collagen formation and fibril organization) were upregulated in IBD Chips upon exposure to cyclic mechanical deformations (**Extended** **Fig. 6A**). In addition, our transcriptomic analysis revealed that expression of different cytochrome P450 subunits was suppressed in IBD versus Healthy Chips, which is consistent with the observation that the intestinal tissues of IBD patients experience decreased metabolic activities35,36. Importantly, while peristalsis-like cyclic deformations increased the expression of most of these metabolic genes in Healthy Chips, this response was not observed in IBD Chips (**Extended Data Fig. 6B**).

Peristalsis-like cyclic deformations also increased barrier function in both Healthy and IBD Chips; however, barrier leakiness always remained higher in IBD Chips (**Extended Data Fig. 7A**). Mechanical stimulation also enriched expression of inflammation associated genes in epithelial cells and fibroblasts in both Healthy and IBD Chips (**Fig. 2G**) and this was supported by transcriptomic analysis, which showed activation of the inflammatory response pathway in these cells (**Extended Data Fig. 7B**). Importantly, further pathway analysis of this transcriptomic dataset (**Extended Data Fig. 8**) demonstrated that peristalsis-like deformations activate pathways associated with IBD progression and exacerbation in the epithelium, including those involved in cancer, Toll-like receptor signaling, PPAR signaling, and focal adhesion in IBD epithelium (**Extended Data Fig. 9A**) as well as NOD-like receptor signaling, PDGF signaling, and cytokine-cytokine receptor interaction in IBD fibroblasts (**Extended Data Fig. 9B**). In contrast, these pathways that are known to exacerbate colitis in IBD patients37,38 were not activated in Healthy Chips under the same mechanical stimulation conditions.

### Replicating Sex-Specific Clinical Symptoms of IBD Patients

The gastrointestinal symptoms of female IBD patients become much more prominent during menstrual periods2 and their therapies need to be optimized to control their symptoms before pregnancy due to increased risk to the fetus3. Yet, it is not known whether these responses are a direct effect of ovarian hormones on the intestine39. To address this question directly, we exposed healthy and IBD Chips lined by cells from female patients to estrogen (E2) and medroxyprogesterone acetate (MPA) to recapitulate the menstrual cycle or a mixture of pregnancy-associated hormones (E2, MPA, human chorionic gonadotropin, prolactin, and placental lactogen) to mimic the first trimester of pregnancy. Interestingly, exposure to E2, MPA or the pregnancy-associated hormone mixture decreased inflammatory cytokine and chemokine production in Healthy Chips whereas levels of these inflammatory molecules increased when IBD Chips were exposed to the same hormones (**Fig. 3A****).** Moreover, addition of E2 and MPA increased fibrosis and exposure to the pregnancy-associated hormone mixture produced an even greater increase in fibrillar collagen deposition in the stroma of IBD Chips; however, this was not observed in Healthy Chips (**Fig. 3B,C****).**

### Stromal Fibroblasts Control Barrier Permeability and Epithelial Inflammation

To better understand the role of fibroblasts in IBD, we took advantage of the synthetic biology nature of human Organ Chip technology to create chips lined by heterotypic tissue recombinants of healthy epithelium with IBD stroma and vice versa. As expected, the homotypic cultures of IBD epithelium and stroma had a compromised barrier with higher permeability than healthy epithelium and stroma recombinants (**Fig. 4A**). However, we discovered that the presence of the IBD fibroblasts was the key driver of barrier disruption as permeability increased significantly when they were combined healthy epithelium in tissue recombinant chips, even though there was no difference in permeability when the different epithelia were cultured alone (**Fig. 4A****)**. Interestingly, the permeability of the IBD epithelium alone (i.e., without IBD stroma) was similar to that of healthy epithelium with or without healthy fibroblasts, and tissue recombinants combining healthy fibroblasts with IBD epithelium also did not further alter barrier function, again emphasizing the key role of that the IBD stroma plays in terms of compromising intestinal barrier function.

![Figure 4:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F4.medium.gif)

[Figure 4:](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F4)

Figure 4: 
**Tissue recombinant chips reveal that the IBD fibroblasts drive compromise of the permeability barrier and inflammation in the epithelium**. **A)** Graphs showing that intestinal barrier permeability to cascade blue is much higher in homotypic IBD Chips compared to Healthy Chips and that tissue recombinants of IBD fibroblasts with healthy (H) epithelium results in a similar high level of barrier compromise on-chip. This is not observed in the IBD or healthy epithelium in the absence of fibroblasts or in IBD epithelium with healthy fibroblasts. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n = 3 healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **B)** Quantification of cytokine protein levels revealed that combination of IBD fibroblasts with healthy epithelium results in increased production of IL-6 and MCP-1 in Colon Chips, whereas this was not seen in healthy epithelium alone or homotypic Colon Chips. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n = 3 healthy, green; 1 Crohn’s, magenta; and 2 UC, cyan). **C)** IL-6 and MCP-1 production by IBD epithelium also required the presence of IBD fibroblasts. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n = 3 healthy, green; 1 Crohn’s, magenta; and 2 UC, cyan). **D)** Peristalsis-like cyclic strain preferentially stimulates migration of PBMCs (magenta) from the fibroblast stroma in the basal channel (Basal) to the epithelium in the apical channel (Apical) in IBD Chips but not in heterotypic chips with IBD epithelium and healthy fibroblasts or in Healthy Chips. **E)** Quantification of the results from **D** confirmed that IBD Chips exhibited higher baseline recruitment of PBMCs to the surface of the fibroblast stroma in the basal channel and that this was not altered by mechanical strain, whereas IBD epithelium combined with healthy stroma or Healthy Chips only displayed significantly less PBMC recruitment. In contrast, the number of PBMCs that migrated to the epithelium in the Apical channel more than doubled in IBD Chips when they were exposed to peristalsis-like mechanical deformations, and overall migration of PBMCs was minimal when IBD fibroblasts were absent. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n = 2 healthy, green; 1 Crohn’s, magenta; and 1 UC, cyan).

This controlling effect of IBD fibroblasts on barrier function when combined with healthy epithelium was also accompanied by increased production of multiple inflammatory cytokines and chemokines including IL-6, MCP-1 (**Fig. 4B**), IL-8, CXCL-1, LIF, IL-21, PIGF-1, and MIP-1b (**Extended Data Fig. 10A**) relative to chips lined by healthy fibroblasts and epithelium or healthy epithelium alone. However, the IBD epithelium appeared to constitutively express high levels of all these cytokines regardless of whether or not IBD fibroblasts were present or they were replaced with healthy fibroblasts, except for production of IL-6 and MCP-1 that were further enhanced by the presence of the IBD stroma (**Fig. 4C** and **Extended Data Fig. 10B**). As these two cytokines are known to promote monocyte infiltration into stroma from the vascular system and their differentiation to macrophages cells40, we perfused human peripheral blood mononuclear cells (PBMCs) through the basal channel of the Colon Chips. We found that more PBMCs adhered to the stroma and migrated to the epithelial channel in the IBD Chips compared to Healthy Chips (**Fig. 4D**). While application of peristalsis-like deformations did not alter PBMC adhesion to the stroma in the basal channel, it significantly enhanced the migration of these cells to the epithelium in the apical channel, but only in IBD Chips (**Fig. 4E**). However, when we carried out a similar study in a heterotypic tissue recombinant chip containing IBD epithelium with healthy fibroblasts, PBMC recruitment and migration were suppressed and reverted to the low levels observed in Healthy Chips (**Fig. 4D,E**). This finding correlates well with transcriptomic analysis, which revealed that multiple surface receptors for immune cell adhesion are expressed at higher levels in fibroblasts and epithelium in IBD Chips versus Healthy Chips (**Extended Data Fig. 10C**). IBD Chips co-cultured with PBMCs also showed increased production of IL-6 and IL-8 in both their apical and basal channels, whereas this was not observed when Healthy Chips (**Extended Data Fig. 10D**).

### Modeling Early Cancer Progression in Human IBD Chips

Patients with IBD have a higher incidence of colorectal cancer formation41 and this also has been demonstrated in animal IBD models by exposing them to the carcinogen ENU42.

When we exposed Healthy and IBD Chips created with cells from multiple different donors to ENU (1 mM) for 3 weeks, we observed a decrease in the height of crypt-like structures (**Fig. 5A,B**) and an increase in barrier permeability (**Fig. 5C**) in both in healthy and IBD Chips.

![Figure 5:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F5.medium.gif)

[Figure 5:](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F5)

Figure 5: Exposure to carcinogen preferentially promotes mutagenesis and early steps in carcinogenesis in IBD Chips.
**A)** DIC images of the epithelium when viewed from above in Healthy (H) and IBD Chips after 21 days of culture in the presence or absence of the carcinogen (ENU) showing that undulating crypt-like structures are lost in both Healthy and IBD Chips after exposure to ENU (bar, 500 µm). **B)** Quantification of results from **A** showing that ENU decreases height of the epithelium in both healthy and IBD Colon Chips. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test (n = 4 healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **C)** Epithelial barrier permeability increased as a result of exposure to ENU in Healthy and IBD Chips. Numbers indicate *P* values between compared groups, as determined by one-way ANOVA test. (n = 3 healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **D)** Heatmaps showing inflammatory cytokine protein levels measured in outflows from the apical channel of Healthy and IBD Chips 3 weeks post-ENU exposure. Importantly, ENU exposure significantly increased inflammatory cytokine production in IBD Chips made with cells from both Crohn’s and UC patients compared to healthy patients. **E)** Confocal microscopic top-view images showing β-catenin and E-cadherin localization and nuclear staining (DAPI) in the epithelium within Healthy and IBD Chips 3 weeks post-ENU exposure (bar, 20 μm). **F)** Quantification of protein staining intensity and morphology reveal that ENU exposure decreases E-cadherin levels and increases nuclear localization of β-catenin in IBD patient-derived Colon Chips compared to Healthy Chips. ENU exposure also resulted in greater nucleus size and less roundness. Numbers indicate *P* values between compared groups, as determined by Student’s t-test (n = 3 healthy, green; 2 Crohn’s, magenta; and 2 UC, cyan). **G)** Plots showing copy number changes across all human chromosomes in Healthy and IBD Chips pre- (red) and 3 weeks post-ENU exposure (blue). Green bars indicate amplification of gene sequences for the whole chromosome. Each symbol represents an individual Healthy or IBD patient-derived chip.

However, ENU had a much greater impact on inflammatory cytokine secretion in the IBD Chips (**Fig. 5D**) and it resulted in a greater reduction of E-cadherin expression in IBD Chips versus Healthy Chips, which was accompanied by a concomitant increase in *β*-catenin translocation to the nucleus (**Fig. 5E,F**). Similar activation of the *β*-catenin signaling pathway has previously been shown to be associated with colorectal cancer progression43. In addition, ENU treatment promoted enlargement of epithelial nuclei and a decrease in their roundness, which are also known to accompany early carcinogenesis44. Importantly, shallow pass genome sequencing revealed increased gene mutations and duplication in IBD Chips, but not in Healthy Chips (**Fig. 5G**). Interestingly, the Crohn’s chips exhibited a higher level of gene amplification than chips lined with cells from UC patients, and an existing mutation in one Crohn’s patient was further amplified after ENU exposure.

## Discussion

Taken together, these findings show that human Colon Chips created with primary patient-derived colonic epithelium and fibroblasts from both healthy and IBD patients recapitulate many features of their respective healthy and diseased phenotypes that are observed in vivo. Based on its synthetic nature, this model enabled exploration of the roles of stromal fibroblasts, epithelium, and immune cells, as well as fluid flow and peristalsis-like mechanical deformations in the etiology of this disease. Importantly, our results revealed that the stroma is a key driver of the IBD phenotype as it is appears to drive effects on intestinal permeability, inflammation, and immune cell infiltration in human intestinal tissues. The finding that IBD stromal fibroblasts respond differently to physiological peristalsis motions than healthy fibroblasts and exhibits enhanced inflammation and fibrotic responses while fluid flow was maintained constant also suggests that physiological mechanical deformations of intestine during early stages of IBD development may feed back to further enhance inflammation and fibrosis thereby accelerating disease progression. In addition, we found that ovarian hormones influence the IBD phenotype directly by targeting the intestinal stroma. The greater enhancement of inflammation and fibrosis we observed when IBD Chips were exposed to these female hormones could be at least in part explain the exacerbation of IBD symptoms observed in women versus men, particularly during pregnancy. Finally, we demonstrated that the human IBD Chips also exhibit an enhanced sensitivity to a carcinogen and undergo changes that underlie early stages of carcinogenesis in vitro, which is again consistent with the finding that IBD patients have an increased propensity to develop colorectal cancers.

Our finding that intestinal stromal fibroblasts influence immune cell trafficking is consistent with a past study in which knock out of genes expressed in an inflammatory subset of fibroblasts produced a similar effect in a mice DSS colitis model12. These results raise the possibility that human Colon Chips could be used as a preclinical model with IBD patient cells to study the effects of emerging immune cell targeting therapies (e.g., anti-integrin α4β7 to suppress infiltration of circulating T-cells) on IBD stroma versus epithelium and to determine their potential efficacy in a patient-specific manner45. In addition, this work might serve as inspiration to develop other stroma-targeted therapies given our findings that the stroma is a key driver of the IBD state in both females and males. The stroma also plays a critical role in intestinal homeostasis by supporting the intestinal stem cell niche growth and modulating immune responses, as well as protection against microbiota46.

Another novel feature of this study is its relevance for Women’s Health. Female IBD patients can experienced loose and increased stools during the menstrual cycle as well as greater fetal complications during pregnancy 39,47. However, it has not been possible in the past to explore whether or not these symptoms are the result of direct effects of female hormones on intestinal tissues. This is because female hormone research is challenging using animals. For example, mice that are often used for women’s health research48 do not menstruate like humans do (e.g., they undergo an estrous cycle) and their immune responses different significantly from human49. Consistent with clinical observations, we found that female hormones exacerbate inflammation and fibrosis in IBD Chips, but not in Healthy Chips, with pregnancy-like conditions producing even greater effects. Thus, these data demonstrate for the first time that at least part of the excerbations observed in female patients is likely due to direct effects on the intestinal tissues, and particular on the stroma where fibrosis is greatly enhanced.

In addition to increased inflammation and decreased mucus production, lack of intestinal motion due to fibrosis is a hallmark of IBD; however, it has not been previously possible to explore whether peristalsis plays a role in earlier stages of IBD progression. We found that peristalsis-like mechanical deformations increased production of the protective mucus layer in Healthy Chips, but less so in IBD Chips, and that these mechanical cues also enhanced inflammation and fibrosis, but only in IBD Chips. This suggests that persistence of physiological peristalsis during early stages of inflammation may promote progression of IBD, and that fibrosis and resultant suppression of peristalsis likely occur at a later stage in this process. This may, in part, occur because the IBD tissues lose their ability to maintain the mucus barrier that protects against dysbiotic microbiome and pathogens that are known to be enriched in the microbiome of IBD patients, such as *Ruminococcus* family members that degrade mucus50. This could then lead to more inflammation and a positive feedback loop characterized by enhanced sensitivity to these mechanical deformations resulting in greater increases in inflammation, ECM accumulation, and fibrosis at later stages of the disease, which stiffens the mucosa and physically restricts tissue distension.41

Chronic inflammation in patients with IBD is known to be a risk factor for increased cancer formation. Importantly, our results show that human IBD tissues do indeed exhibit an enhanced sensitivity to a carcinogen (ENU) compared to Healthy colon tissues on-chip, as indicated by crypt blunting, loss of adherent junctions, and localization of **β**-catenin to the nucleus as seen in IBD patient tissues that progressed to colorectal cancer51. Importantly, we also observed a greatly increased inflammatory response as well as accelerated development of cancer- associated mutations and chromosomal amplifications in IBD Chips but not Healthy Chips, even though immune cells were not present. While similar effects have been observed after exposure to ENU in a murine intestine model 52, this to our knowledge is the first demonstration of early cancer progression in a preclinical *human* IBD model. Although it has been believed that both Crohn’s and UC patients carry a similarly high risk of cancer progression 53, many Crohn’s patients undergo colectomy early in the course of the disease to alleviate persistent symptoms54, and this effectively eliminates their risk of developing colorectal cancer.59 Interestingly, although our sampling was small, we found that ENU induced greater gene and chromosomal aberrations in Crohn’s patient tissues than in UC patient chips, suggesting that they might exhibit a greater susceptibility to carcinogens. This is a finding which should be followed up in clinical studies in the future.

The incidence of IBD is anticipated to increase in the upcoming years. Limitations in the ability of in vivo models to represent human IBD physiology are evident, as the most commonly used anti-TNF and anti-IL-12/23p40 antibodies, which benefit patients with IBD, are generally not effective in chemically-induced colitis models55. The need for modeling IBD using Organ Chip technology also has been acknowledged by leading IBD organizations, such as the Crohn’s and Colitis Foundation56. Therefore, we believe this novel microfluidic disease model brings important opportunities for IBD treatment, management, and drug development. As we can analyze outflows from the epithelial and stromal compartments separately and through use of tissue recombinants, this method also may facilitate discovery of potential stool and blood biomarkers of IBD progression and cancer risk. Use of tissue recombinants is a powerful method for analyzing epithelial-mesenchymal interactions in commonly used developmental biology research, which as we show here also may be applied to confront similar questions relating to human epithelial-stromal interactions, which are challenging to address in vivo. In addition to enabling study of the effects of female hormones on IBD, and it also could allow investigation of other IBD subcategories, including very early onset (VEO-IBD), adolescent IBD, and genetic forms of the disease by lining chips with relevant patient cells. Finally, given the synthetic nature of the model and as living gut microbiome can be co-cultured in these Intestine Chips for extended times15,57, this experimental system also may be used to study how other environmental factors (e.g., pathogens, diet, etc.) contribute to development of the IBD phenotype in the future.

## Methods

### Acquisition of human colon tissue and cells

Healthy colon tissue samples were collected from macroscopically grossly unaffected regions of the colon of de-identified healthy adult patients undergoing endoscopy for non-IBD related complaints, such as diverticulitis. IBD tissue samples were collected from endoscopic tissue biopsies from newly diagnosed IBD patients with either Crohn’s disease or Ulcerative Colitis. Informed consent and developmentally appropriate assent were obtained at Boston Children’s Hospital and McGill University Health Centre from the donors’ guardians and the donor, respectively. All methods were performed in accordance with the Institutional Review Board of Massachusetts General Hospital approval (protocol number IRB-2015P001859) and McGill University Health Centre (protocol number REB-2007-856). We generated epithelium- derived organoids (colonoids) that were cultured in Matrigel using published methods13,15and isolated stromal fibroblasts from the same IBD tissues from 3 Crohn’s and 3 UC patients, which were cultured in fibroblast medium (FM, CC-3132, Lonza, MA) in 75 cm2 flasks (3531135, Falcon, Durham, NC). Healthy colonoids and fibroblasts were isolated from areas with normal histology adjacent to regions of diverticulitis from 3 otherwise healthy patients (**Supplementary Table 1**). All reagents and resources were provided in **Supplementary Table 2**.

### Human Colon Chip Cultures

Our methods for creating and culturing human Colon Chips lined by primary intestinal organoid-derived epithelium using commercially available Organ Chip Devices (Basic Research Kit; Emulate Inc.) have been described previously13,16 and are described in greater detail in Supplementary Materials. Colonoids cultured were released from Matrigel and fragmented by treatment with TrypLE Express Enzyme (12605010; Thermo Fisher Scientific), before being seeded in the apical channel of the 2-channel Organ Chip devices and incubated overnight at 37° C under 5% CO2 to promote adhesion. One day later, channels were washed with Expansion Medium (EM; Harvard Digestive Diseases Center Organoid Core, MA) to remove unattached cells, and then perfused with EM (60 µL/hr). At this time, the cultured fibroblasts were detached enzymatically and seeded in EM in the basal channel for 2 h under static conditions to promote adhesion. After washing, EM was then perfused through both channels at 60 μL/h. After 3 days of co-culture during which both epithelial and fibroblast monolayers were established, EM perfused through the apical channel was changed to Hank’s balanced salt solution (HBSS) with calcium and magnesium (21-023-cv; Corning) supplemented with 100 mg/mL Primocin (ant-pm-1; InvivoGen) while EM remained flowing through the basal channel. For experiments exploring the role of physiological peristalsis-like motions, cyclic mechanical strain (10% Strain 0.15 Hz) was applied to the tissues by applying cyclic suction to side chambers of the flexible device15,16 for 2 weeks after seeding. Methods for morphological analysis, cytokine quantification, flow cytometry, transcriptional analysis, and atomic force microscopy can be found in **Supplementary Information**.

## Maternal Hormone Treatment

Established Healthy and IBD Colon Chips were exposed to different combinations of hormones from basal channel to recapitulate either the menstrual cycle or first trimester of pregnancy. Chips were treated with 17β-estradiol (E2, 10 nM, Sigma, E4389) for 3 days before being exposed to medroxyprogesterone 17-acetate (MPA, 1 μM, Sigma, 46412-250MG) for an additional 4 days to mimic the menstrual period of the cycle. Chips perfused for 3 days with E2 were then treated with E2, MPA, Prolactin (PRL, 20 ng/mL, VWR, 103681-334), Human Placental Lactogen (hPL/ CSH1, 20 ng/ml, VWR, 103681-334), and Human Chorionic Gonadotropin (HCG, 1 μg/mL, VWR, IC0219859110) for 4 days to recapitulate the first trimester of pregnancy as described previously17,18.

### Immune Cell Recruitment Assay

Colon Chips were cultured for 2 weeks before human peripheral blood mononuclear cells (PBMCs) were added to the cultures for studies on immune cell adhesion and migration. PBMCs were collected from anonymous donors undergoing stem cell mobilization at the Massachusetts General Hospital (MGH) under Institutional Review Board approved protocol #2015P001859. PBMCs were freshly isolated by density centrifugation using the Lymphoprep protocol (StemCell Technologies, #07801), resuspended in 10 ml of DMEM containing 10% FBS and 1% Penicillin-Streptomycin, and labeled with 10 µl of CellTracker Deep Red at a final concentration of 10 µM (Invitrogen, #C7025) for 20 minutes at 37°C. The labeled cells were centrifuged and resuspended to a concentration of 5 × 10⁷ cells/ml and 25 µl of the PBMC suspension was added to the lower channel (see **Supplementary Information** for more details).

### Analysis of effects of carcinogen exposure

To explore if the chip models can be used to study the effects of intestinal tissue to carcinogen exposure in vitro, Healthy and IBD Colon Chips were exposed to 1 μg/mL of N-ethyl- N-nitrosourea (ENU), which was flowed through both the apical and basal channels at 60 μL/hr.

Chips were harvested for DNA isolation three weeks after ENU exposure. Briefly, chips were washed with DPBS (-/-) and incubated with TrypLE consisting of 2 mg/mL collagenase and 10 μM Y-27632 at 37°C for 1 h. Single cells were washed with DPBS (-/-) and DNA was isolated by following the manufacturer’s protocol (Qiagen Micro DNA isolation kit, Cat: 56304 Qiagen, Germany). Shallow whole genome sequencing was performed in two batches using different methods (see **Supplementary Information**). The raw sequence reads were mapped to *Homo sapiens* GRCh38 with Burrows-Wheeler Alignment Tool v0.7.1719. Reads with a mapping quality of less than 37 were removed from further analysis. The PCR duplicates and base quality recalibration were subsequently carried out using Genome Analysis Toolkit (GATK) v4.4.020 and Picard v2.27.5. The copy number of the genome was then estimated and profiled with ACE v3.1621 and QDNAseq v1.35.0 R package22 using 100 Mb fixed-sized bins.

### Statistical Analysis

Data in all graphs are expressed as mean ± standard deviation (SD) and significant differences between multiple groups were determined using an unpaired Students t-test, one- way analysis of variance (ANOVA) or two-way ANOVA with Tukey test for correction unless otherwise indicated in the figure legends. P<0.05 was considered significant. Data were analyzed using GraphPad Prism 8 software (GraphPad Software, San Diego, CA).

## Supporting information

Supplemnetary Files [[supplements/318563_file03.pdf]](pending:yes)

## Data Availability

Data that support the findings of this study are available within the paper and its Supplementary Information files. The RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) with the accession code GSE277964. Any other material including the R code used for data analysis is available upon reasonable request.

## Contributions

A.O., S.H. and D.E.I designed the research; A.O., G.E.M, R.R.P. A.S. K. C., E. C. performed the experiments; A.O., G.E.M., R.R.P. A.S., K.C., E.C. analyzed and interpreted the data; A.O. and G.E.M. established IBD human organoid and fibroblast biobanks; V. H., M. S. and A.O. performed bioinformatic analysis; D.B.C., L.E.F., R.R., L.B. provided the clinical samples; A.O. and D.E.I. acquired the funding; A.O. wrote the articled with input from G.G., S.H. and D.E.I.; and all authors reviewed, discussed and edited the manuscript.

## Data and code availability

Data that support the findings of this study are available within the paper and its Supplementary Information files. The RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) with the accession code GSE277964. Any other material including the R code used for data analysis is available upon reasonable request.

## Competing interests

D.E.I. holds equity in Emulate, chairs its scientific advisory board and is a member of its board of directors. The other authors declare no competing interests.

![Extended Data Fig. 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F6.medium.gif)

[Extended Data Fig. 1.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F6)

Extended Data Fig. 1. 

![Extended Data Fig. 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F7.medium.gif)

[Extended Data Fig. 2.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F7)

Extended Data Fig. 2. 

![Extended Data Fig. 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F8.medium.gif)

[Extended Data Fig. 3.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F8)

Extended Data Fig. 3. 

![Extended Data Fig. 4.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F9.medium.gif)

[Extended Data Fig. 4.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F9)

Extended Data Fig. 4. 

![Extended Data Fig. 5.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F10.medium.gif)

[Extended Data Fig. 5.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F10)

Extended Data Fig. 5. 

![Extended Data Fig. 6.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F11.medium.gif)

[Extended Data Fig. 6.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F11)

Extended Data Fig. 6. 

![Extended Data Fig. 7.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F12.medium.gif)

[Extended Data Fig. 7.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F12)

Extended Data Fig. 7. 

![Extended Data Fig. 8.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F13.medium.gif)

[Extended Data Fig. 8.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F13)

Extended Data Fig. 8. 

![Extended Data Fig. 9.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F14.medium.gif)

[Extended Data Fig. 9.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F14)

Extended Data Fig. 9. 

![Extended Data Fig. 10.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2024/12/08/2024.12.05.24318563/F15.medium.gif)

[Extended Data Fig. 10.](http://medrxiv.org/content/early/2024/12/08/2024.12.05.24318563/F15)

Extended Data Fig. 10. 

## Acknowledgement

This work was funded in part by Cancer Research UK (C19767/A27145 to DEI) and by the Wyss Institute for Biologically Inspired Engineering at Harvard University as well as by an NIH training grants (5T32DK007199-44 and 5T32EB016652-10 to AO). We thank Harvard Digestive Diseases Center Organoid Core for providing L-WRN conditioned media.

*   Received December 5, 2024.
*   Revision received December 5, 2024.
*   Accepted December 8, 2024.


*   © 2024, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at [http://creativecommons.org/licenses/by-nd/4.0/](http://creativecommons.org/licenses/by-nd/4.0/)

## References

1.  1.Friedrich, M. et al. IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med 27, 1970– 1981 (2021).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-021-01520-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34675383&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

2.  2.Goodman, W. A., Erkkila, I. P. & Pizarro, T. T. Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 2020 17:*12* 17, 740–754 (2020).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32901108&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

3.  3.Watermeyer, G. Pregnancy and inflammatory bowel disease. South African Gastroenterology Review 5, 4–6 (2007).
    
    

4.  4.Sarvestani, S. K. et al. Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. Oncotarget 9, 28717–28730 (2018).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18632/oncotarget.25617&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29983891&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

5.  5.Ingber, D. E. Cancer as a disease of epithelial–mesenchymal interactions and extracellular matrix regulation. Differentiation 70, 547–560 (2002).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1046/j.1432-0436.2002.700908.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12492496&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

6.  6.Smillie, C. S. et al. Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell 178, 714–730.e22 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cell.2019.06.029&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31348891&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

7.  7.Rieder, F. & Fiocchi, C. Intestinal fibrosis in IBD - A dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 6, 228–235 (2009).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nrgastro.2009.31&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19347014&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000265854200010&link_type=ISI) 

8.  8.Guglielmo, F. F. et al. Identifying decreased peristalsis of abnormal small bowel segments in Crohn’s disease using cine MR enterography: the frozen bowel sign. Abdom Imaging 40, 1150–1156 (2015).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25326259&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

9.  9.Joshi, A., Soni, A. & Acharya, S. In vitro models and ex vivo systems used in inflammatory bowel disease. In vitro models 2022 1:*3* 1, 213–227 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s44164-022-00017-w&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=37519330&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

10. 10.Özkan, A., LoGrande, N. T., Feitor, J. F., Goyal, G. & Ingber, D. E. Intestinal organ chips for disease modelling and personalized medicine. Nat Rev Gastroenterol Hepatol 1–23 (2024) doi:10.1038/s41575-024-00968-3.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41575-024-00968-3&link_type=DOI) 

11. 11.Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet 23, 467–491 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41576-022-00466-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35338360&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

12. 12.Gustafsson, J. K. & Johansson, M. E. V. The role of goblet cells and mucus in intestinal homeostasis. Nat Rev Gastroenterol Hepatol 19, 785–803 (2022).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41575-022-00675-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=36097076&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

13. 13.Sontheimer-Phelps, A. et al. Human Colon-on-a-Chip Enables Continuous In Vitro Analysis of Colon Mucus Layer Accumulation and Physiology. Cmgh 9, 507–526 (2020).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31778828&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

14. 14.Tovaglieri, A. et al. Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites. Microbiome 7, 1–21 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s40168-019-0702-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30606251&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

15. 15.Jalili-Firoozinezhad, S. et al. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nat Biomed Eng 3, 520–531 (2019).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31086325&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

16. 16.Tovaglieri, A. et al. Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites. Microbiome 7, 1–21 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s40168-019-0702-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30606251&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

17. 17.Turco, M. Y. et al. Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium. Nat Cell Biol 19, 568–577 (2017).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/ncb3516&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28394884&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

18. 18.Gnecco, J. S. et al. Organoid co-culture model of the human endometrium in a fully synthetic extracellular matrix enables the study of epithelial-stromal crosstalk. Med 4, 554–579.e9 (2023).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=37572651&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

19. 19.Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/bioinformatics/btp324&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19451168&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000267665900006&link_type=ISI) 

20. 20.Genomics in the Cloud: Using Docker, GATK, and WDL in Terra - Geraldine A. Van der Auwera, Brian D. O’Connor - Google Books. https://books.google.com/books?hl=en&lr=&id=vsXaDwAAQBAJ&oi=fnd&pg=PP1&dq=Vn+der+Auwera+GA+%26+O%27Connor+BD.+(2020).+Genomics+in+the+Cloud:+Using+Docker,+GATK,+and+WDL+in+Terra+(1st+Edition).+O%27Reilly+Media.&ots=5lcr0E-qna&sig=43MTbQQNO_yexxB7NxDgVt88kOk#v=onepage&q&f=false.
    
    

21. 21.Poell, J. B. et al. ACE: absolute copy number estimation from low-coverage whole- genome sequencing data. Bioinformatics 35, 2847–2849 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/BIOINFORMATICS/BTY1055&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30596895&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

22. 22.Scheinin, I. et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 24, 2022–2032 (2014).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiZ2Vub21lIjtzOjU6InJlc2lkIjtzOjEwOiIyNC8xMi8yMDIyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTIvMDgvMjAyNC4xMi4wNS4yNDMxODU2My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

23. 23.Chan, C. W. M. et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX. Proc Natl Acad Sci U S A 106, 1936–1941 (2009).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMDoiMTA2LzYvMTkzNiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI0LzEyLzA4LzIwMjQuMTIuMDUuMjQzMTg1NjMuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

24. 24.West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23, 579–589 (2017).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nm.4307&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28368383&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

25. 25.Wu, J. et al. Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic processes to attenuate acute and chronic colitis in mice. Biomedicine & Pharmacotherapy 168, 115648 (2023).
    
    

26. 26.Torres, J. et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology 159, 96–104 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1053/j.gastro.2020.03.007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32165208&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

27. 27.Danese, S., Sans, M. & Fiocchi, C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 53, 1035 (2004).
    
    

28. 28.Liu, Z. et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat Genet 55, 796 (2023).
    
    

29. 29.Tian, T., Wang, Z. & Zhang, J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev 2017, 4535194 (2017).
    
    

30. 30.Stokkers, P. C. F., Reitsma, P. H., Tytgat, G. N. J. & Van Deventer, S. J. H. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 45, 395 (1999).
    
    

31. 31.Yu, W. et al. Association of a Nkx2-3 polymorphism with Crohn’s disease and expression of Nkx2-3 is up-regulated in B cell lines and intestinal tissues with Crohn’s disease. J Crohns Colitis 3, 189–195 (2009).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.crohns.2009.04.003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21172269&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

32. 32.WO2019018571A1 - Methods and uses of inflammatory bowel disease biomarkers - Google Patents. [https://patents.google.com/patent/WO2019018571A1/en](https://patents.google.com/patent/WO2019018571A1/en).
    
    

33. 33.Srivastava, M., Zurakowski, D., Cheifetz, P., Leichtner, A. & Bousvaros, A. Elevated Serum Hepatocyte Growth Factor in Children and Young Adults With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 33, 548–553 (2001).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/00005176-200111000-00007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11740227&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000172744900007&link_type=ISI) 

34. 34.Cheng, C. et al. Identification of differentially expressed genes, associated functional terms pathways, and candidate diagnostic biomarkers in inflammatory bowel diseases by bioinformatics analysis. Exp Ther Med 18, 278–288 (2019).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31258663&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

35. 35.Wilson, A. et al. Crohn’s Disease Is Associated with Decreased CYP3A4 and P- Glycoprotein Protein Expression. Mol Pharm 16, 4059–4064 (2019).
    
    

36. 36.Sen, A. & Stark, H. Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis. World J Gastroenterol 25, 2846 (2019).
    
    

37. 37.Dubuquoy, L. et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55, 1341 (2006).
    
    

38. 38.Ashton, J. J. et al. Deleterious Genetic Variation Across the NOD Signaling Pathway Is Associated With Reduced NFKB Signaling Transcription and Upregulation of Alternative Inflammatory Transcripts in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 28, 912–922 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34978330&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

39. 39.Lim, S. M. et al. The effect of the menstrual cycle on inflammatory bowel disease: A prospective study. Gut Liver 7, 51–57 (2013).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.5009/gnl.2013.7.1.51&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23423645&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000313775600008&link_type=ISI) 

40. 40.Chomarat, P., Banchereau, J., Davoust, J. & Karolina Palucka, A. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature Immunology 2000 1:*6* 1, 510–514 (2000).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/82763&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11101873&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000165724600015&link_type=ISI) 

41. 41.Murphy, C. C. & Zaki, T. A. Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol 21, 25–34 (2023).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=37723270&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

42. 42.Schmitt, M. & Greten, F. R. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol 21, 653–667 (2021).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33911231&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

43. 43.Herzig, M., Savarese, F., Novatchkova, M., Semb, H. & Christofori, G. Tumor progression induced by the loss of E-cadherin independent of β-catenin/Tcf-mediated Wnt signaling. Oncogene 26, 2290–2298 (2007).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/sj.onc.1210029&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17043652&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000245466000005&link_type=ISI) 

44. 44.Zink, D., Fischer, A. H. & Nickerson, J. A. Nuclear structure in cancer cells. Nature Reviews Cancer 2004 4:*9* 4, 677–687 (2004).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nrc1430&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15343274&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000223657800012&link_type=ISI) 

45. 45.D’Alessio, S. et al. Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol 19, 169–184 (2022).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34876680&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

46. 46.Ryan, F. J. et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat Commun 11, 1–12 (2020).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41467-019-13889-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31911652&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

47. 47.Mendelson, S., Anbukkarasu, P., Cassisi, J. E. & Zaman, W. Gastrointestinal functioning and menstrual cycle phase in emerging young adult women: a cross-sectional study. BMC Gastroenterol 23, 1–10 (2023).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=36593456&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

48. 48.Bellofiore, N., Ellery, S., Mamrot, J., … D. W.-A. journal of & 2017, undefined. First evidence of a menstruating rodent: the spiny mouse (Acomys cahirinus). Elsevier.
    
    

49. 49.Bellofiore, N., Cousins, F., Temple-Smith, P., Dickinson, H. & Evans, J. A missing piece: the spiny mouse and the puzzle of menstruating species. J Mol Endocrinol 61, R25–R41 (2018).
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoiam1lIjtzOjU6InJlc2lkIjtzOjg6IjYxLzEvUjI1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjQvMTIvMDgvMjAyNC4xMi4wNS4yNDMxODU2My5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

50. 50.Paone, P. & Cani, P. D. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut 69, 2232 (2020).
    
    

51. 51.Aust, D. E. et al. Altered distribution of β-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Modern Pathology 14, 29–39 (2001).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/modpathol.3880253&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11211307&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000166622400006&link_type=ISI) 

52. 52.Winton, D. J. & Ponder, B. A. J. Stem-cell organization in mouse small intestine. Proc Biol Sci 241, 13–18 (1990).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1098/rspb.1990.0059&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=1978330&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

53. 53.Winawer, S. J. et al. Colorectal Cancer Screening: Clinical Guidelines and Rationale The Adenoma-Carcinoma Sequence. Gastroenterology 112, 594–642 (1997).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1053/gast.1997.v112.agast970594&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9024315&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1997WF18500035&link_type=ISI) 

54. 54.Gillen, C. D., Walmsley, R. S., Prior, P., Andrews, H. A. & Allan, R. N. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35, 1590 (1994).
    
    

55. 55.Pizarro, T. T. et al. Challenges in IBD Research: Preclinical Human IBD Mechanisms. Inflamm Bowel Dis 25, S5–S12 (2019).
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31095706&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

56. 56.Heller, C. A. et al. Challenges in IBD Research. Inflamm Bowel Dis 25, S31–S39 (2019).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ibd/izz078&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 

57. 57.Kim, H. J., Huh, D., Hamilton, G. & Ingber, D. E. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12, 2165–2174 (2012).
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1039/c2lc40074j&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22434367&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F12%2F08%2F2024.12.05.24318563.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000304448700009&link_type=ISI)